Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Nature Biotechnology is Scopus-indexed (Q1, CiteScore 66.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Nature Research.
Checked against the index lists dated .
ISSN 1087-0156Verify ISSN ↗1546-1696Verify ISSN ↗
Publisher: Nature Research
Cost to publish: About US$12,690 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Biomedical Engineering | 1 / 342 | 99th | Q1 |
| Biotechnology | 1 / 325 | 99th | Q1 |
| Molecular Medicine | 1 / 179 | 99th | Q1 |
| Bioengineering | 1 / 168 | 99th | Q1 |
| Applied Microbiology and Biotechnology | 1 / 134 | 99th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1989–present, best quartile Q1, CiteScore 66.4.
Nature Biotechnology is Q1 in Biomedical Engineering (rank 1 of 342), Q1 in Biotechnology (rank 1 of 325) and Q1 in Molecular Medicine (rank 1 of 179), by CiteScore 2025. It is ranked in 5 subject areas in all.
Nature Biotechnology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 66.4, which places it in quartile Q1 at the 99th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 23.109, quartile Q1, with an H-index of 553.
The publisher lists an article processing charge of about US$12,690 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Nature Biotechnology is published by Nature Research. Its print ISSN is 1087-0156 and its online ISSN is 1546-1696.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Nature Biotechnology has an h-index of 642 and a 2-year mean of 12.89 citations per paper (OpenAlex). Its Scopus CiteScore is 66.4, quartile Q1. On 2-year citations it ranks #8 of 322 Scopus journals in Biomedical Engineering.
Nature Biotechnology published 437 papers in 2025; its busiest recent year was 2024 with 468. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 55 research articles (2026), authors are most often from United States (50.9%), China (15.5%) and United Kingdom (6.8%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 10 retracted papers are recorded (0.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.